On March 6, 2014, Insmed Incorporated (NASDAQ: INSM) reported financial results for the three and twelve months ended December 31, 2013. The Company will not hold a quarterly conference call to discuss these results given the proximity to the scheduled announcement in late March of top-line results from its phase 2 clinical trial with ARIKAYCE® to treat nontuberculous mycobacteria (NTM) lung infections. The Company plans to hold a conference call at that time. Insmed Incorporated (NASDAQ:INSM) stock opened at $17.85 in last trading session, and closed at $18.91, trading in the range of $17.45 – $19.13. The stock showed a positive weekly performance of 4.65%.
Stock analysts at Stifel Nicolaus initiated coverage on shares of Chimerix (NASDAQ:CMRX) in a report issued on Thursday, Stock Ratings Network reports. The firm set a “buy” rating and a $34.00 price target on the stock. Stifel Nicolaus’ price target would suggest a potential upside of 38.32% from the company’s current price. Chimerix Inc (NASDAQ:CMRX) shares closed at $26.40 on last trade day, by gaining 7.40%. Stock 52 week range is $12.96 – $27.00. Company’s market capitalization is $706.54 million.
Medical Action Industries (NASDAQ:MDCI), announced that it has signed a definitive agreement to sell its Medegen Medical Products, LLC subsidiary and certain other assets of its Patient Care business unit to Medira Inc., an affiliate of Inteplast Group, Ltd. (“Inteplast”), for approximately $75 million, subject to certain purchase price adjustments. The transaction is expected to close upon receipt of the required regulatory approvals and the satisfaction of other closing conditions agreed to by the parties. The Company anticipates completion of these regulatory approvals and closing conditions within three to four months. Medical Action Industries (NASDAQ:MDCI) stock advanced 7.65% and finished the last session at $7.46. The EPS of the stock remained 0.24. Company’s market capitalization is $122.27 million.
On March 4, 2014, Celladon Corp (NASDAQ:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced it has completed enrollment and randomized 250 patients in the phase 2b trial titled “Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease,” known as CUPID 2, which is evaluating the efficacy and safety of MYDICAR (AAV1/SERCA2a) in patients with NYHA class III/IV symptoms of systolic heart failure. Celladon Corp (NASDAQ:CLDN) shares closed at $14.66 on last trade day, by gaining 8.27%. Stock 52 week range is $7.45 – $15.48. Company’s market capitalization is $271.21 million.